Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hahn

Showing results (1151-1160 of 1,198) with videos related to

Pageof 120
Sort By:
Nature Structural & Molecular Biology|September 22, 2023
Time-resolved cryo-EM (TR-EM) analysis of substrate polyubiquitination by the RING E3 anaphase-promoting complex/cyclosome (APC/C)Tatyana Bodrug, Kaeli A Welsh, Derek L Bolhuis, et al.
The Journal of Urology|September 16, 2020
Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial CarcinomaXiao X Wei, Lillian Werner, Min Y Teo, et al.
The Journal of Urology|June 20, 2020
Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 InhibitorsGuru Sonpavde, Juliane Manitz, Chen Gao, et al.
Cancer Research|November 9, 2016
Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by RadiotherapyXiaohong Wang, Jonathan E Schoenhals, Ailin Li, et al.
British Journal of Cancer|October 16, 2018
A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumoursAmit Maity, Rosemarie Mick, Alexander C Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2020
Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial CancerMatthew D Galsky, Amir Mortazavi, Matthew I Milowsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 2004
A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancerNeil E Martin, Thomas B Brunner, Krystina D Kiel, et al.
Cell Reports|August 7, 2024
Regulation of MYC by CARD14 in human epithelium is a determinant of epidermal homeostasis and diseaseStanley B DeVore, Matthew Schuetz, Lauren Alvey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2020
Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate CancerJames A Eastham, Glenn Heller, Susan Halabi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2011
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancerToni K Choueiri, Robert W Ross, Susanna Jacobus, et al.
Pageof 120

Showing results (1151-1160 of 1,198) with videos related to

Sort By:
Pageof 120
Nature Structural & Molecular Biology|September 22, 2023
Time-resolved cryo-EM (TR-EM) analysis of substrate polyubiquitination by the RING E3 anaphase-promoting complex/cyclosome (APC/C)Tatyana Bodrug, Kaeli A Welsh, Derek L Bolhuis, et al.
The Journal of Urology|September 16, 2020
Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial CarcinomaXiao X Wei, Lillian Werner, Min Y Teo, et al.
The Journal of Urology|June 20, 2020
Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 InhibitorsGuru Sonpavde, Juliane Manitz, Chen Gao, et al.
Cancer Research|November 9, 2016
Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by RadiotherapyXiaohong Wang, Jonathan E Schoenhals, Ailin Li, et al.
British Journal of Cancer|October 16, 2018
A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumoursAmit Maity, Rosemarie Mick, Alexander C Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2020
Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial CancerMatthew D Galsky, Amir Mortazavi, Matthew I Milowsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 2004
A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancerNeil E Martin, Thomas B Brunner, Krystina D Kiel, et al.
Cell Reports|August 7, 2024
Regulation of MYC by CARD14 in human epithelium is a determinant of epidermal homeostasis and diseaseStanley B DeVore, Matthew Schuetz, Lauren Alvey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2020
Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate CancerJames A Eastham, Glenn Heller, Susan Halabi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2011
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancerToni K Choueiri, Robert W Ross, Susanna Jacobus, et al.
Pageof 120